Home > Name List By g > Gallium nitrate

CAS No 13494-90-1 , Gallium nitrate

  • Name: Gallium nitrate
  • Synonyms: GALLIUM NITRATE, 99.9%; Nitric acid, gallium salt; Gallium trinitrate;Gallium (III) nitrate (1:3);Gallium nitrate;
  • CAS Registry Number:
  • Transport: 1477
  • Melting Point: 110°C (dec.)
  • Flash Point: °C
  • Boiling Point: 83°Cat760mmHg
  • Density: 1.623g/cm3
  • Safety Statements: Poison by intraperitoneal, intravenous, and subcutaneous routes. Moderately toxic by ingestion. Human systemic effects by intravenous route: nausea or vomiting, renal function changes, proteinuria, normocytic anemia, and thrombocytopenia. A severe skin irritant. Mutation data reported. When heated to decomposition it emits toxic fumes of NOx. See also NITRATES.
  • Flash Point: °C
  • EINECS: 236-815-5
  • Molecular Weight: GaN3O9
  • InChI: InChI=1/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1
  • Risk Statements: 8-36/37/38
  • Molecular Formula: 255?7347
  • Molecular Structure:CAS No:13494-90-1 Gallium nitrate
References of Gallium nitrate
Title: Gallium Nitrate
CAS Registry Number: 13494-90-1
CAS Name: Nitric acid gallium salt
Synonyms: gallium trinitrate
Manufacturers' Codes: NSC-15200
Trademarks: Ganite (Genta)
Molecular Formula: GaN3O9
Molecular Weight: 255.74
Percent Composition: Ga 27.26%, N 16.43%, O 56.31%
Line Formula: Ga(NO3)3
Literature References: Formed by the reaction of elemental gallium with nitric acid; alters the mineral, matrix, and cellular properties of bone. Prepn: A. Dupré, C.R. Hebd. Seances Acad. Sci. 86, 720 (1878); of octahydrate: E. Einecke, Angew. Chem. 55, 40 (1942); of nonahydrate: R. Reinmann, A. Tanner, Z. Naturforsch. 20b, 71 (1965). Toxicity and antitumor activity: M. M. Hart et al., J. Natl. Cancer Inst. 47, 1121 (1971). Clinical pharmacokinetics: D. P. Kelsen et al., Cancer 46, 2009 (1980). Clinical trial in Paget's disease: R. S. Bockman et al., J. Clin. Endocrinol. Metab. 80, 595 (1995). Review of properties and clinical development: B. J. Foster et al., Cancer Treat. Rep. 70, 1311-1319 (1986); of clinical studies in treatment of bone metastases: R. P. Warrell, Jr., Cancer 80, 1680-1685 (1997); of therapeutic uses: G. Apseloff, Am. J. Ther. 6, 327-339 (1999). Series of articles on pharmacology and mechanism of action: Semin. Oncol. 18, Suppl. 5, 1-31 (1991); on clinical experience in multiple myeloma, lymphoma, bladder cancer and cancer-related hypercalcemia: ibid. 30, Suppl. 5, 1-41 (2003).
Properties: White crystalline powder. Sol in warm and cold aqueous solvents, absolute alcohol, ether.
 
Derivative Type: Nonahydrate
CAS Registry Number: 135886-70-3
Properties: White, slightly hygroscopic, crystalline powder. Sol in water. LD50 in male mice, female rats (mg/kg): 80.0, 67.5 i.p. (Hart).
Toxicity data: White, slightly hygroscopic, crystalline powder. Sol in water. LD50 in male mice, female rats (mg/kg): 80.0, 67.5 i.p. (Hart)
 
Derivative Type: Octahydrate
Properties: mp ~65°.
Melting point: mp ~65°
 
Therap-Cat: Antineoplastic; antipagetic; bone resorption inhibitor.
Keywords: Antineoplastic; Antipagetic; Bone Resorption Inhibitor.